Authorship

All authors must meet the authorship criteria of ‘Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals’ listed on https://www.icmje.org/. Qualifying for authorship is required for all authors and the order of authorship is to be decided between the coauthors. The authorship credit should be based on substantial contributions to: (1) conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; (2) drafting the work or reviewing it critically for important intellectual content; (3) final approval of the version to be published; (4) agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Any persons who do not meet the 4 criteria above should be placed as contributors in Acknowledgments section.

Generative artificial intelligence (AI) including language models, chatbots, image creators, machine learning, or similar technologies do not qualify for authorship. The technologies listed above may be used in enhancing readability and language accuracy in scientific writing. The responsibility for the manuscript's integrity ultimately rests with the human authors, and the authors employing generative AI tools in manuscript preparation are required to disclose their use in the Acknowledgments section. Such disclosure should detail the specific tools used, including the model name, version, and manufacturer, and explain the capacity in which they were employed. Should the use of AI extend beyond language enhancement, the methods and tools used must be detailed in the Materials and methods section as a formal part of the research design.

One author should be chosen to act as a corresponding author. The corresponding author does not have to be the first author. The corresponding author will be responsible for the entire communications to/from the Editorial Office, editors and etc. In case of multicenter studies, a corporate author directly responsible for the manuscript should be appointed.

Correction of authorship: Any requests for such changes in authorship (adding author(s), removing author(s), or rearranging the order of authors) after the initial manuscript submission and before publication should be explained in writing to the editor in a letter or email from all authors. This letter must be signed by all authors of the paper. A copyright assignment must be completed by every author.

Redundant publication and plagiarism

Attempting to publish substantially similar work more than once without attribution of the original source(s) is considered a redundant publication. Definition of being substantially similar can be explained as follows:

• At least one of the authors is common to all reports (it is likely to be plagiarism if there are no common authors);
• The subject or study populations are same or similar;
• The methodology is typically identical or nearly so and;
• The results and interpretation varies little or not at all.

If all or part of the subject population has been reported previously, it should be declared in the Materials and Methods and must be appropriately referenced. In cases where authors are concerned with any potential overlap with published manuscripts or manuscripts being reviewed, the authors must include a letter explaining how the manuscript submitted to JKMI significantly differs from other materials. For more information, please refer to ‘Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication’ (Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3142758/).

Secondary publication

It is possible to republish manuscripts if the manuscripts satisfy the conditions of secondary publication of the ICMJE Recommendations (http://www.icmje.org/urm_main.html).

Process for managing research and publication misconduct

When the Journal faces suspected cases of research and publication misconduct such as a redundant (duplicate) publication, falsification of data, plagiarism, improprieties of authorship, undisclosed conflicts of interest, misappropriation of the ideas of others, violation of generally accepted research practices, material failure to comply with legislative and regulatory requirements affection research, inappropriate behavior in relation to misconduct, the resolving process will follow the flowchart provided by the Committee on Publication Ethics (https://publicationethics.org/resources/flowcharts). The Editorial Board will discuss the suspected cases and reach a decision. We will not hesitate to publish errata, corrigenda, clarifications, retractions, and apologies when needed.

Editorial responsibilities

The Editorial Board will continuously work to monitor and safeguard publication ethics: guidelines for retracting articles; maintenance of the integrity of the academic record; preclusion of business needs from compromising intellectual and ethical standards; publishing corrections, clarifications, retractions, and apologies when needed; and excluding plagiarism and fraudulent data. The editors maintain the following responsibilities: responsibility and authority to reject and accept articles; avoiding any conflict of interest with respect to articles they reject or accept; promoting publication of corrections or retractions when errors are found; and preservation of the anonymity of reviewers.

Conflict of interest statement

The corresponding author must inform the editor of any potential conflicts of interest that could influence the authors’ interpretation of the data. Examples of potential conflicts of interest are financial support from or connections to companies, political pressure from interest groups, and academically related issues. In particular, all sources of funding applicable to the study should be explicitly stated.

Human and animal rights

Clinical research should be conducted in accordance with the World Medical Association’s Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects (https://www.wma.net/what-we-do/medical-ethics/declaration-of-helsinki/). Clinical studies that do not meet the Helsinki Declaration will not be considered for publication. For human, identifiable information, such as patients’ names, initials, hospital numbers, dates of birth, or other protected healthcare information should not be disclosed. For animal subjects, research should be performed based on the National or Institutional Guide for the Care and Use of Laboratory Animals, and the ethical treatment of all experimental animals should be maintained.

Clinical trial registration

Any research that deals with a clinical trial should be registered in the primary national clinical trial registry site, such as the Korea Clinical Research Information Service (CRIS, https://cris.nih.go.kr), any other primary national registry site accredited by the World Health Organization (https://www.who.int/clinical-trials-registry-platform), or ClinicalTrials.gov (https://clinicaltrials.gov), a service of the U. S. National Institutes of Health.

Statement of informed consent and institutional review board approval

Copies of written informed consents should be kept for studies on human subjects. For clinical studies with human subjects, there should be a certificate, agreement, or approval by the institutional review board (IRB) of the author’s affiliated institution. If necessary, the editor or reviewers may request copies of these documents to resolve questions about IRB approval and study conduct.